Key result
Statins linked to a phenotypic shift from supravalvular to valvular aortic stenosis in HoFH.
Why the study?
Are statins contributing to the phenotypic shift from supravalvular to valvular aortic stenosis in homozygous familial hypercholesterolaemia?
Are statins contributing to the phenotypic shift from supravalvular to valvular aortic stenosis in homozygous familial hypercholesterolaemia?
This paper discusses the hypothesis that statin therapy may contribute to a phenotypic shift from supravalvular to valvular aortic stenosis in patients with homozygous familial hypercholesterolemia.
Answers are grounded in this paper and cite their sources.
Should not alter statin use in HoFH; hypothesis-generating observation requiring prospective validation.
Graphical Abstract LLT, lipid lowering therapies; Lp(a), lipoprotein(a); VAS, valvular aortic stenosis; SVAS, supravalvular aortic stenosis.
No takes yet. Share an insight, caveat, or question.
Bajaj et al. (2022) studied this question. Statins may contribute to a phenotypic shift from supravalvular to valvular aortic stenosis in patients with homozygous familial hypercholesterolaemia.
Synapse has enriched 10 related papers. Consider them for comparative context: